Oncology

Latest News

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com
Patient Navigation Is Nonnegotiable in Cancer Care

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Second-Line NSCLC Coverage Decisions
May 12th 2017

Second-Line NSCLC Coverage Decisions

Molecular Testing Coverage Decisions in Lung Cancer
May 12th 2017

Molecular Testing Coverage Decisions in Lung Cancer

Communicating Policy Changes in Lung Cancer
May 12th 2017

Communicating Policy Changes in Lung Cancer

Clinical Pathways in NSCLC
May 12th 2017

Clinical Pathways in NSCLC

Lung Cancer: Novel Combinations
May 12th 2017

Lung Cancer: Novel Combinations

The REVEL Study in Lung Cancer
May 12th 2017

The REVEL Study in Lung Cancer

Alternative Payment Models and Quality in Lung Cancer
May 12th 2017

Alternative Payment Models and Quality in Lung Cancer

Rationale for Anti-Angiogenesis in Lung Cancer
May 12th 2017

Rationale for Anti-Angiogenesis in Lung Cancer

Role of Immunotherapy in Lung Cancer
May 12th 2017

Role of Immunotherapy in Lung Cancer

Deciding on Second-Line Lung Cancer Therapy
May 12th 2017

Deciding on Second-Line Lung Cancer Therapy

Frontline Decision Making in Nondriver Lung Cancer
May 12th 2017

Frontline Decision Making in Nondriver Lung Cancer

Outcomes-Based Contracting in Lung Cancer
May 12th 2017

Outcomes-Based Contracting in Lung Cancer

Cost-Benefit Analysis in Lung Cancer
May 12th 2017

Cost-Benefit Analysis in Lung Cancer

Current Biomarkers in Lung Cancer
May 12th 2017

Current Biomarkers in Lung Cancer

Assessing Options in Second-Line NSCLC
May 12th 2017

Assessing Options in Second-Line NSCLC

Molecular Testing in NSCLC and Cost
May 12th 2017

Molecular Testing in NSCLC and Cost

Integrating New Lung Cancer Drugs Into a Formulary
May 12th 2017

Integrating New Lung Cancer Drugs Into a Formulary

Clinical Pathways in Lung Cancer
May 12th 2017

Clinical Pathways in Lung Cancer

Site Logo
May 12th 2017

Nine Months in: Understanding the Oncology Care Model

Jessica Walradt
As we near the first anniversary of the Oncology Care Model, CMS' bundled payment program for oncology, explore why practices are participating and the challenges they have faced over the past 9 months.
Site Logo
May 11th 2017

Pembrolizumab Plus Chemotherapy Approved for Metastatic Nonsquamous NSCLC

Surabhi Dangi-Garimella, PhD
Tumor response rate and progression-free survival were the benchmarks that helped pembrolizumab (Keytruda) gain accelerated approval as first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), in combination with chemotherapy.
Site Logo
May 11th 2017

Survival Inequalities in Childhood Leukemia Remain Large Worldwide, Despite Progress

Laura Joszt, MA
While global inequalities for survival of childhood leukemia have narrowed, the gap remains wide for acute lymphoblastic leukemia and acute myeloid leukemia, according to a study published in The Lancet Haematology. In some countries, the 5-year survival rate is nearly twice as high as in others for children diagnosed in 2005-2009.
Site Logo
May 10th 2017

USPSTF: Do Not Screen for Thyroid Cancer in Asymptomatic Individuals

Surabhi Dangi-Garimella, PhD
The US Preventive Services Task Force (USPSTF) has provided a D recommendation (discourages the use of service) for thyroid cancer screening in asymptomatic individuals.
The Future of Healthcare in the United States
May 10th 2017

The Future of Healthcare in the United States

How Will an ACA Repeal Affect Healthcare?
May 10th 2017

How Will an ACA Repeal Affect Healthcare?

The Politics of Healthcare Reform
May 10th 2017

The Politics of Healthcare Reform

Navigating Eligibility and Access Issues When Diagnosed
May 10th 2017

Navigating Eligibility and Access Issues When Diagnosed

The Balancing Act of Cost vs Access to Care
May 10th 2017

The Balancing Act of Cost vs Access to Care

Role of Health Plans in Medicaid Expansion
May 10th 2017

Role of Health Plans in Medicaid Expansion

ACA, Medicaid Expansion, and Cancer Care
May 10th 2017

ACA, Medicaid Expansion, and Cancer Care

ACA: Effect on Patients With Chronic Conditions
May 10th 2017

ACA: Effect on Patients With Chronic Conditions

<1
...
737475767778798081
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo